◎ Sugi Atlas

Atlas / Disease / Morbid obesity

Morbid obesity

disease
On this page

Summary

Morbid obesity (MONDO:0005139) is a disease with 2 cohort genes (90 GWAS associations across 8 studies) and 418 clinical trials. Top therapeutic interventions include neostigmine, fondaparinux, and phentermine.

At a glance

  • Cohort genes: 2
  • GWAS associations: 90
  • ClinVar variants: 2
  • Clinical trials: 418

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namemorbid obesity
Mondo IDMONDO:0005139
EFOEFO:0001074
MeSHD009767
DOIDDOID:11981
SNOMED CT83911000119104
UMLSC0028756
MedGen18128
Is cancer (heuristic)no

Data availability: 2 ClinVar variants · 90 GWAS associations (8 studies) · 50 cell lines.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › nutritional disorder › overnutrition › obesity disorder › morbid obesity

Related subtypes (1): inherited obesity

Genetics & variants

GWAS landscape

90 GWAS associations across 8 studies. Top hits map to 20 distinct genes (as reported by GWAS).

Top associations by p-value

rsIDp-valueGeneRisk alleleOdds ratio
rs14210851e-173FTOT0.18
rs15589027e-122FTOT0.18
rs348724715e-48TCF7L2T0.1
rs79031466e-36TCF7L2C0.09
chr4:451825271e-30A0.07
rs18004377e-27GIPRG0.09
rs130283104e-26LINC01875 - TMEM18T0.09
chr2:2270937451e-25T0.07
rs105138012e-25ETV5T0.11
rs126419819e-25PRDX4P1 - THAP12P9C0.07
rs22386911e-24GIPRG0.09
rs28204492e-24LYPLAL1-AS1G0.07
rs131073251e-23SLC39A8C0.12
rs133870912e-23LINC01875 - TMEM18G0.09
rs71329085e-22FAIM2G0.06
chr7:766342691e-21G0.08
rs25689523e-21LINC02796C0.07
chr2:589163364e-21C0.06
rs68096512e-20ETV5G0.09
chr18:578504225e-20G0.07
chr3:123904842e-19T0.09
rs65671607e-19LINC03111 - RNU4-17PT0.07
rs128837883e-18AKAP6C0.06
rs29436471e-17NYAP2 - MIR5702T0.06
rs8796202e-17ADCY9C0.06
chr6:390038744e-17A0.06
rs47769708e-17MAP2K5A0.06
chr11:474319662e-16C0.06
rs588620953e-16POM121CC0.06
rs4787883e-16LINC01741 - SEC16BT0.07

Top studies (by case count)

StudyLead authorYearCasesControlsTitle
GCST90475765Verma A202445,933385,784Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90475764Verma A202414,258101,561Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90479951Verma A202414,258101,561Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90081528Backman JD20217,973142,553Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90085514Backman JD20217,973142,553Exome sequencing and analysis of 454,787 UK Biobank participants.
GCST90475763Verma A20245,87151,265Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651236Liu TY20251,369231,349Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.
GCST90481638Verma A20242026,509Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

TierVariants
Tier 1: coding2
Tier 2: splice/UTR3
Tier 3: regulatory0
Tier 4: intronic/intergenic45

MAF distribution

BucketVariants
common (>=0.05)50
low_freq (0.01-0.05)0
rare (<0.01)0
unknown0

Functional consequences

ConsequenceCount
unknown20
intron_variant19
intergenic_variant5
3_prime_UTR_variant3
missense_variant2
non_coding_transcript_exon_variant1

Top variants

rsIDChrPosAllelesMAFConsequenceGenep-valueTier
rs14210851653767042T>C0.406intron_variantFTO1e-173Tier 4: intronic/intergenic
rs15589021653769662T>A0.329intron_variantFTO7e-122Tier 4: intronic/intergenic
rs3487247110112994312T>C0.293intron_variantTCF7L25e-48Tier 4: intronic/intergenic
rs790314610112998590C>G,T0.29intron_variantTCF7L26e-36Tier 4: intronic/intergenic
chr4:451825270.4321e-30Tier 4: intronic/intergenic
rs18004371945678134G>A,C0.208missense_variantGIPR7e-27Tier 1: coding
rs130283102632591T>A,C,G0.186intergenic_variantLINC01875 - TMEM184e-26Tier 4: intronic/intergenic
chr2:2270937450.3541e-25Tier 4: intronic/intergenic
rs105138013186104564T>G0.128intron_variantETV52e-25Tier 4: intronic/intergenic
rs12641981445177866C>T0.387intergenic_variantPRDX4P1 - THAP12P99e-25Tier 4: intronic/intergenic
rs22386911945675785G>A0.182intron_variantGIPR1e-24Tier 4: intronic/intergenic
rs28204491219541657G>A0.325intron_variantLYPLAL1-AS12e-24Tier 4: intronic/intergenic
rs131073254102267552C>A,T0.083missense_variantSLC39A81e-23Tier 1: coding
rs133870912650980G>A0.158intergenic_variantLINC01875 - TMEM182e-23Tier 4: intronic/intergenic
rs71329081249869365G>A,C0.3873_prime_UTR_variantFAIM25e-22Tier 2: splice/UTR
chr7:766342690.2221e-21Tier 4: intronic/intergenic
rs2568952172289422C>G0.397intron_variantLINC027963e-21Tier 4: intronic/intergenic
chr2:589163360.4064e-21Tier 4: intronic/intergenic
rs68096513186096853G>A0.141intron_variantETV52e-20Tier 4: intronic/intergenic
chr18:578504220.2325e-20Tier 4: intronic/intergenic
chr3:123904840.1242e-19Tier 4: intronic/intergenic
rs65671601860161902T>C0.213intergenic_variantLINC03111 - RNU4-17P7e-19Tier 4: intronic/intergenic
rs128837881432834334C>A,T0.4713_prime_UTR_variantAKAP63e-18Tier 2: splice/UTR
rs29436472226235259T>C,G0.313intergenic_variantNYAP2 - MIR57021e-17Tier 4: intronic/intergenic
rs879620163965728C>A,G,T0.4033_prime_UTR_variantADCY92e-17Tier 2: splice/UTR
chr6:390038740.3484e-17Tier 4: intronic/intergenic
rs47769701567788548A>C,G,T0.359intron_variantMAP2K58e-17Tier 4: intronic/intergenic
chr11:474319660.322e-16Tier 4: intronic/intergenic
rs58862095775452145C>G,T0.395intron_variantPOM121C3e-16Tier 4: intronic/intergenic
rs4787881177917883T>C0.227intron_variantLINC01741 - SEC16B3e-16Tier 4: intronic/intergenic

ClinVar germline variants

2 retrieved; paginated sample, class counts are floors:

1 benign, 1 uncertain significance

ClinVarVariant (HGVS)GeneClassificationReview
8130NM_138711.6(PPARG):c.248C>A (p.Pro83Gln)PPARGUncertain significancecriteria provided, multiple submitters, no conflicts
7578NM_003356.4(UCP3):c.824+1G>AUCP3Benigncriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 5 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
PPARGOrphanet:146Differentiated thyroid carcinoma
PPARGOrphanet:251576Gliosarcoma
PPARGOrphanet:251579Giant cell glioblastoma
PPARGOrphanet:696242PPARG-associated congenital generalized lipodystrophy
PPARGOrphanet:79083PPARG-related familial partial lipodystrophy

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence2

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
UCP3HGNC:12519ENSG00000175564P55916Putative mitochondrial transporter UCP3clinvar
PPARGHGNC:9236ENSG00000132170P37231Peroxisome proliferator-activated receptor gammaclinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
UCP3Putative mitochondrial transporter UCP3Putative transmembrane transporter that plays a role in mitochondrial metabolism via an as yet unclear mechanism.
PPARGPeroxisome proliferator-activated receptor gammaLigand-activated transcription factor that forms obligate heterodimers with the retinoic acid receptor and acts as a key regulator of biological processes, such as adipocyte differentiation, lipid metabolism, glucose homeostasis and beta-o…

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Nuclear receptor1192.9×0.010
Transporter138.9×0.026

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
UCP3TransporteryesMCP, MCP_transmembrane, MCP_dom_sf
PPARGNuclear receptoryesNucl_hrmn_rcpt_lig-bd, Znf_hrmn_rcpt, Nuclear_hrmn_rcpt

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)2
unknown0

Top tissues across cohort

TissueCohort genes
gastrocnemius1
hindlimb stylopod muscle1
muscle of leg1
adipose tissue of abdominal region1
omental fat pad1
peritoneum1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
UCP3224tissue_specificmarkergastrocnemius, hindlimb stylopod muscle, muscle of leg
PPARG194ubiquitousmarkeromental fat pad, peritoneum, adipose tissue of abdominal region

Protein interactions among cohort

Intra-cohort edges: 1.

Hub genes (top 10 by interactor count)

SymbolInteractor count
PPARG7,747
UCP31,442

Intra-cohort edges

ABSources
PPARGUCP3string_interaction

Structural data

PDB: 1 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
PPARGP37231380

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
UCP3P5591662.65

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 9. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
The fatty acid cycling model11142.0×0.004UCP3
MECP2 regulates transcription factors11142.0×0.004PPARG
Transcriptional regulation of brown and beige adipocyte differentiation by EBF21190.3×0.013PPARG
SUMOylation of intracellular receptors1167.9×0.013PPARG
Nuclear Receptor transcription pathway1100.2×0.017PPARG
Regulation of PTEN gene transcription189.2×0.017PPARG
Transcriptional regulation of white adipocyte differentiation164.9×0.020PPARG
PPARA activates gene expression147.2×0.024PPARG
MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis141.4×0.024PPARG

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
response to nutrient2295.6×9e-04UCP3, PPARG
fatty acid metabolic process2193.7×0.001UCP3, PPARG
lipid hydroperoxide transport14213.0×0.003UCP3
response to fenofibrate14213.0×0.003UCP3
negative regulation of connective tissue replacement involved in inflammatory response wound healing14213.0×0.003PPARG
positive regulation of adiponectin secretion12808.7×0.003PPARG
beige fat cell differentiation12808.7×0.003PPARG
negative regulation of extracellular matrix assembly12106.5×0.003PPARG
negative regulation of cellular response to transforming growth factor beta stimulus12106.5×0.003PPARG
response to superoxide11685.2×0.003UCP3
positive regulation of lipid metabolic process11685.2×0.003PPARG
positive regulation of fatty acid metabolic process11685.2×0.003PPARG
negative regulation of mitochondrial fission11685.2×0.003PPARG
positive regulation of lipoprotein transport11685.2×0.003PPARG
negative regulation of receptor signaling pathway via STAT11685.2×0.003PPARG
negative regulation of vascular endothelial cell proliferation11685.2×0.003PPARG
positive regulation of cholesterol transport11203.7×0.004PPARG
response to lipid11203.7×0.004PPARG
negative regulation of type II interferon-mediated signaling pathway11053.2×0.004PPARG
positive regulation of vascular associated smooth muscle cell apoptotic process11053.2×0.004PPARG
negative regulation of cardiac muscle hypertrophy in response to stress1936.2×0.004PPARG
mitochondrial transmembrane transport1842.6×0.004UCP3
negative regulation of cholesterol storage1766.0×0.004PPARG
negative regulation of lipid storage1766.0×0.004PPARG
peroxisome proliferator activated receptor signaling pathway1766.0×0.004PPARG
regulation of cellular response to insulin stimulus1766.0×0.004PPARG
negative regulation of macrophage derived foam cell differentiation1648.1×0.005PPARG
long-chain fatty acid transport1561.7×0.005PPARG
positive regulation of adipose tissue development1526.6×0.005PPARG
adaptive thermogenesis1526.6×0.005UCP3

Therapeutics

Drugs indicated for this disease

0 approved, 5 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
DexmedetomidinePhase 3 (in late-stage trials)
FentanylPhase 3 (in late-stage trials)
KetaminePhase 3 (in late-stage trials)
LidocainePhase 3 (in late-stage trials)
Sodium ChloridePhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Exenatide, Neostigmine, Onabotulinumtoxina, Phentermine, Propofol, Remifentanil, Sevoflurane, Sugammadex, Tirzepatide.

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 1

Druggability breadth: 1 of 2 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
PPARGMETHYLENE BLUE ANHYDROUS

Top cohort targets by molecule count

SymbolMoleculesMax phase
PPARG834
UCP300

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
METHYLENE BLUE ANHYDROUS4PPARG
BENZBROMARONE4PPARG
BEXAROTENE4PPARG
PIOGLITAZONE HYDROCHLORIDE4PPARG
ROSIGLITAZONE MALEATE4PPARG
CANDESARTAN CILEXETIL4PPARG
TELMISARTAN4PPARG
RIMONABANT4PPARG
CEFAMANDOLE4PPARG
CLOBETASOL PROPIONATE4PPARG
ROSIGLITAZONE4PPARG
FULVESTRANT4PPARG
LIOTHYRONINE4PPARG
SULINDAC4PPARG
CEFTRIAXONE4PPARG
LEVOTHYROXINE4PPARG
CEFOTAXIME4PPARG
CANNABIDIOL4PPARG
TIPRANAVIR4PPARG
EFAVIRENZ4PPARG
PEMAFIBRATE4PPARG
MASOPROCOL4PPARG
LASOFOXIFENE4PPARG
ELAFIBRANOR4PPARG
LUMIRACOXIB4PPARG
TROGLITAZONE4PPARG
CEFTAZIDIME4PPARG
GEMFIBROZIL4PPARG
GLYBURIDE4PPARG
NINTEDANIB4PPARG

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
PPARG2,033Binding:1593, Functional:380, ADMET:56, Toxicity:3, Unclassified:1

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
PPARG2,033

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

29 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

CompoundMax phaseCohort target (bioactivity)
METHYLENE BLUE ANHYDROUS4PPARG
BENZBROMARONE4PPARG
BEXAROTENE4PPARG
PIOGLITAZONE HYDROCHLORIDE4PPARG
ROSIGLITAZONE MALEATE4PPARG
CANDESARTAN CILEXETIL4PPARG
TELMISARTAN4PPARG
RIMONABANT4PPARG
CEFAMANDOLE4PPARG
CLOBETASOL PROPIONATE4PPARG
ROSIGLITAZONE4PPARG
FULVESTRANT4PPARG
LIOTHYRONINE4PPARG
SULINDAC4PPARG
CEFTRIAXONE4PPARG
CEFOTAXIME4PPARG
CANNABIDIOL4PPARG
TIPRANAVIR4PPARG
EFAVIRENZ4PPARG
PEMAFIBRATE4PPARG
MASOPROCOL4PPARG
LASOFOXIFENE4PPARG
ELAFIBRANOR4PPARG
LUMIRACOXIB4PPARG
TROGLITAZONE4PPARG
CEFTAZIDIME4PPARG
GEMFIBROZIL4PPARG
GLYBURIDE4PPARG
NINTEDANIB4PPARG

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)1PPARG
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug1UCP3
EDifficult family or no structure, no drug0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
UCP30PPARG

Clinical trials & evidence

Clinical trials

Clinical trials: 418.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified349
PHASE425
PHASE313
PHASE29
PHASE19
PHASE2/PHASE36
PHASE1/PHASE24
EARLY_PHASE13

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06132477PHASE4RECRUITINGImpact GLP-1 Agonists Following Bariatric
NCT06712199PHASE4NOT_YET_RECRUITINGEffect of Oxalidine Combined with Reduced-opioid Anesthesia on Multimodal Analgesia in Morbidly Obese Patients Undergoing Bariatric Surgery
NCT00331565PHASE4COMPLETEDInvestigations on the Influence of Bariatric Surgery on the Metabolism and Absorption of Atorvastatin
NCT00361985PHASE4WITHDRAWNStudy of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery
NCT00395681PHASE4COMPLETEDPopulation PK/PD of Propofol in the Morbidly Obese Patient
NCT00543140PHASE4COMPLETEDPost Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band
NCT00667706PHASE4UNKNOWNLaparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy
NCT01519726PHASE4COMPLETEDCYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model Drug
NCT01639677PHASE4COMPLETEDClinical Trial Between Laparoscopic Gastric Bypass and Laparoscopic Vertical Banded Gastroplasty for Morbid Obesity
NCT01764555PHASE4COMPLETEDPharmacokinetics of Acetaminophen in Morbidly Obese Patients
NCT01929850PHASE4WITHDRAWNLaparoscopic Sleeve Gastrectomy Plus Weight Watchers vs. Weight Watchers Alone in Underserved Minority Women
NCT02017314PHASE4UNKNOWNVAS Correlation With BMI
NCT02118844PHASE4UNKNOWNLaparoscopic Bariatric Surgery: Impact of Deep Neuromuscular Block on Surgical Conditions
NCT02206256PHASE4COMPLETEDOmega-3 Fatty Acids in Bariatric Gastric Bypass Surgery: Effect on Liver Volume, Immune Response and Erythrocyte Function
NCT02295150PHASE4UNKNOWNProphylaxis of Venous Thromboembolism After Bariatric Surgery
NCT02320604PHASE4COMPLETEDLiposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN)
NCT02616003PHASE4COMPLETEDPreoperative Condition in Giant Obese Patients
NCT02703909PHASE4COMPLETEDSurgical Conditions During Laparoscopic Bariatric Surgery
NCT03074695PHASE4COMPLETEDDPE Technique in Labor Epidural for Morbidly Obese Women
NCT03102658PHASE4COMPLETEDMicafungin Pharmacokinetics in Obese Patients
NCT03246386PHASE4COMPLETEDDosing Obese With Noxafil® Under a Trial (DONUT)
NCT03849729PHASE4COMPLETEDEffectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery
NCT03946657PHASE4COMPLETEDAnesthetics and Cerebral Oxygenation in LSG
NCT04073056PHASE4COMPLETEDEfficacy Of Quadratus Lumborum II Block For Laparoscopic Sleeve Gastrectomy
NCT05856617PHASE4UNKNOWNRemimazolam vs Propofol as an Induction Agent for Morbid Obesity Patients
NCT00434525PHASE3COMPLETEDLaparoscopic Sleeve Gastrectomy With and Without Omentectomy
NCT00434655PHASE3COMPLETEDLaparoscopic Adjustable Gastric Banding Versus Laparoscopic Sleeve Gastrectomy
NCT00872378PHASE2/PHASE3UNKNOWNThe Effects of Exenatide After Gastric Restriction
NCT01249872PHASE2/PHASE3COMPLETEDPatients-Controlled Epidural Analgesia After Gastric Bypass for Morbid Obesity Using Morphine-Levobupivacaine Regimens
NCT01279499PHASE2/PHASE3UNKNOWNSevoflurane Versus Intravenous Anaesthetic Agents in Morbid Obese Patients
NCT01613664PHASE3COMPLETEDEfficiency of TISSEEL for Sleeve Gastrectomy Complications
NCT01629394PHASE2/PHASE3UNKNOWNComparative Study of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Morbidly Obese Patients
NCT01724970PHASE3UNKNOWNLaryngeal Masks for Bariatric Surgery
NCT01724983PHASE3UNKNOWNKetamine in Bariatric Surgery
NCT01774682PHASE3COMPLETEDKinematics of Obese Patients Perambulation
NCT02077517PHASE3UNKNOWNStapled vs Hand Sewn Anastomosis in Roux en Y Gastric Bypass for Morbid Obesity: Randomized Clinical Trial
NCT02122029PHASE3COMPLETEDLifestyle vs.Surgery for Morbid Obesity Treatment
NCT02786108PHASE3UNKNOWNBariatric Arterial Embolization for Morbid Obesity
NCT03211455PHASE3COMPLETEDIntravenous Lidocaine in Bariatric Surgery.
NCT04576975PHASE3UNKNOWNKetamine Infusion vs Dexmedetomidine Infusion in Obese Patients Undergoing Bariatric Surgery

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
NEOSTIGMINE44
FONDAPARINUX43
PHENTERMINE43
ROCURONIUM43
ACETAMINOPHEN41
BACLOFEN41
CHOLECALCIFEROL41
EPHEDRINE41
ESOMEPRAZOLE41
FIBRINOGEN I 12541
GLYCINE41
LEVOBUPIVACAINE41
LEVOTHYROXINE41
LIRAGLUTIDE41
MICAFUNGIN41
MIDAZOLAM41
MORPHINE41
NADROPARIN CALCIUM41
NALBUPHINE41
PROPOFOL41
REMIMAZOLAM BESYLATE41
SETMELANOTIDE41
URSODIOL41
ALANINE31
BEMIPARIN31
POLYGLACTIN 91031
POWDERED CELLULOSE31
TALINOLOL21
TETRAHYDROCANNABIVARIN21
CHEMBL406709002

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 70

This page pulls from 70 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondbsnpdepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncintactinterpromedgenmeshmimmondomondochildmondoparentorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptufeatureumlsuniprot